eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors
16 févr. 2022 08h30 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the...
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference
09 févr. 2022 16h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation...
eFFECTOR Therapeutics Provides Pipeline and Business Updates
24 janv. 2022 16h00 HE
|
eFFECTOR Therapeutics, Inc.
Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient...
eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology
24 nov. 2021 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of...
eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit
22 nov. 2021 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors...
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
08 nov. 2021 07h00 HE
|
eFFECTOR Therapeutics, Inc.
• Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor • Selected...
eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors
01 nov. 2021 16h05 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
26 oct. 2021 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
07 oct. 2021 16h30 HE
|
eFFECTOR Therapeutics, Inc.
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by increasing...
Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
30 sept. 2021 16h32 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...